Clinical trial
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00098124 · Forest Laboratories, Industry · Completed
Key facts
| NCT number | NCT00098124 |
|---|---|
| Title | Study of Milnacipran for the Treatment of Fibromyalgia |
| Official title | A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia |
| Lead sponsor | Forest Laboratories, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | milnacipran hydrochloride |
| Enrollment | 1,200 |
| Start date | Nov 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Dec 6, 2004 |
| Last update posted | Dec 24, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: